PA

Your Article Summary

See Latest Articles

Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial
Diabetic Medicine, 10/01/09

Bansal D et al. – As there are few differences between the two treatments in efficacy, pregabalin 150 mg twice daily might be the alternative choice as it is associated with fewer adverse effects in this population.

• A randomized, double–blind, crossover, active–control, clinical trial with variable dose titration was carried out (n = 51).
• Amitriptyline orally, at doses of 10, 25 and 50 mg at night–time and pregabalin orally, at doses of 75, 150 and 300 mg twice daily, by optional titration was used.
• Each drug treatment was of 5 weeks.
• There was a placebo washout period for 3 weeks between the two drugs. Assessment for pain relief, overall improvement and adverse events were carried out.

• Good, moderate and mild pain relief were noted in 21 (48%), 6 (13%) and 7 (15%) patients on pregabalin and 15 (34%), 5 (11%) and 12 (27%) patients on amitriptyline, respectively, by patient's global assessment of efficacy and safety.
• Patient and physician's global assessment, McGill pain questionnaire, Likert pain scale and Patient Global Impression of Change showed no significant difference between the treatments, although improvement with both treatments was seen from the first week.
• Of the 52 adverse events reported, 34 (65.4%) were with amitriptyline, drowsiness being the commonest [in 19 (43%) patients]. Pregabalin caused adverse events in 18 (25%), of which drowsiness was the most common in nine (20%) patients.
• The preferred pregabalin dose was 150 mg twice daily.

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

U.S. Opioid Risk Management Initiatives
Pain: Clinical Updates (IASP’s clinical newsletter), 11/20/09

Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: The Fremantle Diabetes Study
Diabetes Care, 11/20/09

Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis
Journal of Clinical Endocrinology and Metabolism, 11/20/09

 See all of Clinical Pharmacology

Today in Endocrinology...keeping you current

Receive free subspecialty "5-minute updates" via email

Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: The Fremantle Diabetes Study
Diabetes Care, 11/20/09

Inflammation markers and metabolic characteristics of subjects with one-hour plasma glucose levels
Diabetes Care, 11/20/09

Stress-induced obesity and the emotional nervous system
Trends in Endocrinology and Metabolism, 11/20/09

 See all of Endocrinology

Today in Neurology...keeping you current

Receive free subspecialty "5-minute updates" via email

When should you consider implanted nerve stimulators for lower back pain?
APCToday, 11/20/09

Guidelines for the proper use of epidural steroid injections for the chronic pain patient
Techniques in Regional Anesthesia and Pain Management, 11/20/09

Evidence-based practice of lumbar epidural injections
Techniques in Regional Anesthesia and Pain Management, 11/20/09

 See all of Neurology